MX2023014547A - Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). - Google Patents
Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3).Info
- Publication number
- MX2023014547A MX2023014547A MX2023014547A MX2023014547A MX2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A MX 2023014547 A MX2023014547 A MX 2023014547A
- Authority
- MX
- Mexico
- Prior art keywords
- preparation
- indacen
- hexahydro
- sulfonamide
- piperidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/98—Nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141028180 | 2021-06-23 | ||
| PCT/EP2022/067126 WO2022268935A2 (en) | 2021-06-23 | 2022-06-23 | Novel process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023014547A true MX2023014547A (es) | 2024-04-29 |
Family
ID=82458485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023014547A MX2023014547A (es) | 2021-06-23 | 2022-06-23 | Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240150291A1 (https=) |
| EP (1) | EP4359385A2 (https=) |
| JP (1) | JP2024524215A (https=) |
| KR (1) | KR20240024842A (https=) |
| CN (1) | CN118019727A (https=) |
| AR (1) | AR126215A1 (https=) |
| AU (1) | AU2022300325A1 (https=) |
| CA (1) | CA3219597A1 (https=) |
| IL (1) | IL308071A (https=) |
| MX (1) | MX2023014547A (https=) |
| TW (1) | TW202317514A (https=) |
| WO (1) | WO2022268935A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR128498A1 (es) * | 2022-02-15 | 2024-05-15 | Hoffmann La Roche | Procesos novedosos |
| WO2024133610A1 (en) * | 2022-12-23 | 2024-06-27 | F. Hoffmann-La Roche Ag | Proccesses for the preparation of an nlrp3 inhibitor |
| IL325043A (en) | 2023-08-16 | 2026-01-01 | Hoffmann La Roche | Process for the preparation of 1-ethyl-n-((1,2,3,5,6,7-hexahydro-s-indecen-4-yl)carbamoyl)piperidine-4-sulfonamide |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69727837T2 (de) * | 1997-05-02 | 2004-12-30 | Dr. Reddy's Research Foundation, Hyderabad | Neue antidiabetische verbindungen mit hypolipidimischen und antihypertensiven eigenschaften, verfahren zu ihrer herstellung und ihre enthaltenden arzneimittel |
| HUP0303204A3 (en) * | 2000-11-16 | 2010-04-28 | Sankyo Co | 1-methylcarbapenem derivatives and pharmaceutical compositions containing them |
| WO2002100833A1 (en) * | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Rho KINASE INHIBITORS |
| US7220735B2 (en) * | 2002-04-18 | 2007-05-22 | Schering Corporation | Benzimidazolone histamine H3 antagonists |
| TW200524865A (en) * | 2003-10-08 | 2005-08-01 | Nicholas Piramal India Ltd | Fibrinogen receptor antagonists and their use |
| DOP2006000009A (es) * | 2005-01-13 | 2006-08-15 | Arena Pharm Inc | Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina |
| JP5508027B2 (ja) * | 2007-02-22 | 2014-05-28 | メルク セローノ ソシエテ アノニム | キノキサリン化合物及びその使用 |
| JP5898962B2 (ja) * | 2012-01-11 | 2016-04-06 | 東京応化工業株式会社 | レジスト組成物及びレジストパターン形成方法 |
| WO2017095758A1 (en) * | 2015-12-01 | 2017-06-08 | Merck Sharp & Dohme Corp. | Homobispiperidinyl derivatives as liver x receptor beta agonists, compositions, and their use |
| US11465992B2 (en) * | 2017-07-07 | 2022-10-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| GB201712282D0 (en) * | 2017-07-31 | 2017-09-13 | Nodthera Ltd | Selective inhibitors of NLRP3 inflammasome |
| EP3668861A1 (en) * | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3773576A4 (en) * | 2018-03-26 | 2021-12-29 | C4 Therapeutics, Inc. | Cereblon binders for the degradation of ikaros |
| CR20200588A (es) * | 2018-05-04 | 2021-06-24 | Inflazome Ltd | Compuestos novedosos |
| CA3113573A1 (en) * | 2018-09-21 | 2020-03-26 | Novartis Ag | Isoxazole carboxamide compounds and uses thereof |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| WO2020157069A1 (en) * | 2019-01-28 | 2020-08-06 | NodThera Limited | Amino heterocyclic compounds and uses thereof |
-
2022
- 2022-06-23 WO PCT/EP2022/067126 patent/WO2022268935A2/en not_active Ceased
- 2022-06-23 EP EP22738569.7A patent/EP4359385A2/en active Pending
- 2022-06-23 IL IL308071A patent/IL308071A/en unknown
- 2022-06-23 TW TW111123528A patent/TW202317514A/zh unknown
- 2022-06-23 CA CA3219597A patent/CA3219597A1/en active Pending
- 2022-06-23 KR KR1020237044161A patent/KR20240024842A/ko active Pending
- 2022-06-23 JP JP2023578919A patent/JP2024524215A/ja active Pending
- 2022-06-23 CN CN202280045202.0A patent/CN118019727A/zh active Pending
- 2022-06-23 AU AU2022300325A patent/AU2022300325A1/en active Pending
- 2022-06-23 AR ARP220101651A patent/AR126215A1/es unknown
- 2022-06-23 MX MX2023014547A patent/MX2023014547A/es unknown
-
2023
- 2023-12-19 US US18/545,711 patent/US20240150291A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022268935A3 (en) | 2023-02-02 |
| IL308071A (en) | 2023-12-01 |
| TW202317514A (zh) | 2023-05-01 |
| EP4359385A2 (en) | 2024-05-01 |
| US20240150291A1 (en) | 2024-05-09 |
| CN118019727A (zh) | 2024-05-10 |
| AR126215A1 (es) | 2023-09-27 |
| KR20240024842A (ko) | 2024-02-26 |
| AU2022300325A8 (en) | 2023-11-16 |
| AU2022300325A1 (en) | 2023-11-02 |
| WO2022268935A2 (en) | 2022-12-29 |
| CA3219597A1 (en) | 2022-12-29 |
| JP2024524215A (ja) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014547A (es) | Proceso para la preparacion de inhibidores de familia de receptores tipo nod con dominio pirina 3 (nlrp3). | |
| MX2021004431A (es) | Procesos novedosos. | |
| JOP20210307A1 (ar) | مثبطات جسيم التهابي nlrp3 | |
| WO2024120378A3 (en) | Triazole compounds, preparation methods and medicinal uses thereof | |
| MX2021000925A (es) | Inhibidores de inflamasoma nlrp3. | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| CR20230261A (es) | Cocristal de un inhibidor de cdk | |
| ZA202403388B (en) | Small molecules for treatement of cancer | |
| MX2020011196A (es) | Una sal sodica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamo il)-1-isopropil-1h-pirazol-3-sulfonamida. | |
| GEP20257823B (en) | Amino quinazoline derivatives as p2x3 inhibitors | |
| MX2025002086A (es) | Inhibidores novedosos de inflamasoma nlrp3 | |
| CA3200722A1 (en) | Heteroaryl-acetylenes, pharmaceutical compositions thereof, and their therapeutic applications | |
| MX2022004878A (es) | Derivados de n-(heteroaril)quinazolin-2-amina a manera de inhibidores de lrrk2, composiciones farmaceuticas y usos de los mismos. | |
| MX2025001865A (es) | Compuestos de piridinona sustituida como inhibidores de cbl-b | |
| MX2024008558A (es) | Derivados de piridazinil amino como inhibidores del receptor del factor de crecimiento transformante b de tipo i (alk5). | |
| MX2024014315A (es) | Compuestos amido heteroaromaticos utiles en el tratamiento de enfermedades hepaticas | |
| PH12022551177A1 (en) | Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5 | |
| MX2025014163A (es) | Azinas condensadas como inhibidores de tyk2 y usos de las mismas | |
| MX2025012370A (es) | Compuesto de amida, composicion farmaceutica que comprende el compuesto y uso de esta | |
| MX2023015377A (es) | Sal de potasio cristalina de 1-etil-n-((1,2,3,5,6,7-hexahidro-s-in dacen-4-il)carbamoil)piperidin-4-sulfonamida. | |
| CA3242600A1 (en) | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives | |
| MX2023014784A (es) | Preparacion de derivados de compuestos 1,2-diaminoheterociclicos sustituidos y su uso como agentes farmaceuticos. | |
| WO2022204344A3 (en) | Enamine n-oxides: synthesis and application to hypoxia-responsive prodrugs and imaging agents | |
| ZA202405279B (en) | Heteroaryl derivative and use thereof |